Clinical Trial Detail

NCT ID NCT04209465
Title A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Black Diamond Therapeutics, Inc.
Indications

Advanced Solid Tumor

Therapies

BDTX-189

Age Groups: adult senior

Additional content available in CKB BOOST